Effect of Intranasal Insulin on Postoperative Cognitive Dysfunction
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04154449 |
Recruitment Status :
Recruiting
First Posted : November 6, 2019
Last Update Posted : November 6, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Our study is designed to evaluate the effect of intranasal insulin on postoperative cognitive dysfunction.
Primary outcome:
1. The occurrence of cognitive dysfunction at approximately 7 days after surgery.
Secondary outcome:
1. Incidence of any side effect.
Condition or disease | Intervention/treatment |
---|---|
Middle Aged Patients | Drug: Intranasal insulin |
Study Type : | Observational |
Estimated Enrollment : | 57 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Effect of Intranasal Insulin on Postoperative Cognitive Dysfunction in Middle Aged Patients Undergoing Non Cadiac Surgery. |
Actual Study Start Date : | February 25, 2019 |
Estimated Primary Completion Date : | December 25, 2019 |
Estimated Study Completion Date : | December 25, 2019 |

Group/Cohort | Intervention/treatment |
---|---|
Control group. | |
Surgical group Received intranasal insulin. |
Drug: Intranasal insulin
Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything. |
Surgical group Received placebo. |
- Cognitive dysfunction [ Time Frame: 7 days ]The occurrence of cognitive dysfunction at approximately 7 days after surgery.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
- Age 40 - 60 years.
- Both gender.
- Patients will be scheduled for elective major abdominal, thoracic, orthopedic, open gynecological, open urological, spine, otolaryngological surgeries under general anesthesia with expected hospital stay >4 days.
Inclusion Criteria:
- Age 40 - 60 years.
- Both gender.
- Patients will be scheduled for elective major abdominal, thoracic, orthopedic, open gynecological, open urological, spine, otolaryngological surgeries under general anesthesia with expected hospital stay >4 days.
Exclusion Criteria:
- 1. Drug allergy. 2. Patients with major psychiatric disease. 3. Patients receive major tranquillizers and antidepressant. 4. Those undergoing neurosurgery or cardiac surgery. 5. Those unable or unwilling to abide by the study procedure 6. Those who could not follow procedure or who had poor comprehension of dutch language. 7. Those with sever visual and auditory disorder / handicaps.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04154449
Contact: Nourhan Mohamed Anter | 01100418846 ext 01012660236 | nourhananter1992@yahoo.com |
Egypt | |
Minia University | Recruiting |
Minya, Egypt, 61111 | |
Contact: Nourhan NM Mohamed Anter, Resident 01100418846 nourhananter1992@yahoo.com | |
Minia university | Completed |
Minya, Egypt, 61111 |
Responsible Party: | Nourhan mohamed anter, Resident of anesthesia and Intensive care, Minia University |
ClinicalTrials.gov Identifier: | NCT04154449 |
Other Study ID Numbers: |
164: 2/2019 |
First Posted: | November 6, 2019 Key Record Dates |
Last Update Posted: | November 6, 2019 |
Last Verified: | November 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Cognitive Dysfunction Cognition Disorders Neurocognitive Disorders Mental Disorders |
Insulin Hypoglycemic Agents Physiological Effects of Drugs |